<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0701256529
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AVORES 400 Film Coated Tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIFLOXACIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AVORES contains the active substance Moxifloxacin, which belongs to a group of antibiotics called fluoroquinolones. AVORES works by killing<br />bacteria that cause infections. AVORES is used in patients aged 18 years and above for treating the following bacterial infections when caused by<br />bacteria against which Moxifloxacin is active. AVORES should only be used to treat these infections when usual antibiotics cannot be used or have<br />not worked:<br />□ Infection of the sinuses, sudden worsening of long term inflammation of the airways or infection of the lungs (pneumonia) acquired outside the<br />hospital (except severe cases).<br />□ Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infections of the fallopian tubes and infections<br />of the uterus mucous membrane. AVORES tablets are not sufficient on their own for treating this kind of infection. Therefore, another antibiotic in<br />addition to AVORES tablets should be prescribed by your doctor for the treatment of infections of the female upper genital tract (see section 2.<br />Before you take AVORES, Take special care with AVORES, Talk to your doctor before taking AVORES).<br />If the following bacterial infections have shown improvement during initial treatment with AVORES solution for infusion, AVORES tablets may also<br />be prescribed by your doctor to complete the course of therapy: Infection of the lungs (pneumonia) acquired outside the hospital, infections of the<br />skin and soft tissue. AVORES tablets should not be used to initiate therapy for any type of infections of the skin and soft tissue or in severe<br />infections of the lungs</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contact your doctor if you are not sure if you belong to a patient group described below.<br />Do not take AVORES:<br />□ If you are allergic to the active substance Moxifloxacin, any other quinolone antibiotics or any of the other ingredients of this medicine (listed in<br />section 6.)<br />□ If you are pregnant or are breast-feeding.<br />□ If you are under 18 years of age.<br />□ If you have previously had problems with your tendons related to treatment with quinolone antibiotics (see section Take special care with<br />AVORES and section 4. Possible side effects).<br />□ If you were born with or have:<br />- Any condition with abnormal heart rhythm (seen on ECG, electrical recording of the heart) - A salt imbalance in the blood (especially low levels of<br />potassium or magnesium in the blood) - A very slow heart rhythm (called &lsquo;bradycardia&rsquo;) - A weak heart (heart failure) - A history of abnormal heart<br />rhythms - Or if you are taking other medicines that result in abnormal ECG changes (see section taking other medicines). This is because<br />AVORES can cause changes on the ECG, that is a prolongation of the QT-interval, i.e., delayed conduction of electrical signals.<br />□ If you have a severe liver disease or increased liver enzymes (transaminases) higher than 5 times the upper normal limit.<br />Take special care with AVORES:<br />Talk to your doctor before taking AVORES<br />□ AVORES can change your heart&rsquo;s ECG, especially if you are female, or if you are elderly. If you are currently taking any medicine that decreases<br />your blood potassium levels, consult your doctor before taking AVORES (see also sections: Do not take AVORES and Taking other medicines with<br />AVORES).<br />□ If you suffer from epilepsy or a condition which makes you likely to have convulsions talk to your doctor before taking AVORES.<br />□ If you have or have ever had any mental health problems, consult your doctor before taking AVORES.<br />□ If you suffer from myasthenia gravis (abnormal muscle fatigue leading to weakness and in serious cases paralysis), taking AVORES may worsen<br />the symptoms of your disease. If you think you are affected consult your doctor immediately.<br />□ If you or any member of your family have glucose-6-phosphate dehydrogenase deficiency (a rare hereditary disease), tell your doctor, who will<br />advise whether AVORES is suitable for you.<br />□ If you have a complicated infection of the female upper genital tract (e.g. associated with an abscess of the fallopian tubes and ovaries or of the<br />pelvis), for which your doctor considers an intravenous treatment necessary, treatment with AVORES tablets is not appropriate.<br />□ For the treatment of mild to moderate infections of the female upper genital tract your doctor should prescribe another antibiotic in addition to<br />AVORES. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.<br />When taking AVORES<br />□ If you experience palpitations or irregular heart beat during the period of treatment, you should inform your doctor immediately. He/she may wish<br />to perform an ECG to measure your heart rhythm.<br />□ The risk of heart problems may increase with increase of the dose. Therefore, the recommended dosage should be followed.<br />□ There is a rare chance that you may experience a severe, sudden allergic reaction (an anaphylactic reaction/shock) even with the first dose.<br />Symptoms include tightness in the chest, feeling dizzy, feeling sick or faint, or dizziness when standing up. If so, stop taking AVORES and seek<br />medical advice immediately.<br />□ AVORES may cause a rapid and severe inflammation of the liver which could lead to life-threatening liver failure (including fatal cases, see<br />section 4. Possible side effects). If you suddenly feel unwell and/or are being sick and also have yellowing of the whites of the eyes, dark urine,<br />itching of the skin, a tendency to bleed or liver induced disease of the brain (symptoms of a reduced liver function or a rapid and severe<br />inflammation of the liver) please contact your doctor before taking any more tablets.<br />□ If you develop a skin reaction or blistering / peeling of the skin and/or mucosal reactions (see section 4. Possible side effects) contact your doctor<br />immediately before you continue treatment.<br />□ Quinolone antibiotics, including AVORES, may cause convulsions. If this happens, stop taking AVORES and contact your doctor immediately.<br />□ You may experience symptoms of nerve damage (neuropathy) such as pain, burning, tingling, numbness and/or weakness especially in the feet<br />and legs or hand and arms. If this happens, inform your doctor immediately prior to continuing treatment with AVORES.<br />□ You may experience mental health problems even when taking quinolone antibiotics, including AVORES, for the first time. In very rare cases<br />depression or mental health problems have led to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4. Possible<br />side effects). If you develop such reactions, stop taking AVORES and inform your doctor immediately.<br />□ You may develop diarrhoea whilst or after taking antibiotics including AVORES. If this becomes severe or persistent or you notice that your stool<br />contains blood or mucus you should stop taking AVORES immediately and consult your doctor. You should not take medicines that stop or slow<br />down bowel movement.<br />□ AVORES may cause pain and inflammation of your tendons, even within 48 hours of starting treatment and up to several months after<br />discontinuing AVORES therapy. The risk of inflammation and rupture of tendons is increased if you are elderly or if you are also taking<br />corticosteroids. At the first sign of any pain or inflammation you should stop taking AVORES, rest the affected limb(s) and consult your doctor<br />immediately. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture (see sections Do not take AVORES and 4.<br />Possible side effects).<br />□ If you are elderly and have kidney problems make sure that you drink plenty whilst taking AVORES. If you get dehydrated this may increase the<br />risk of kidney failure.<br />□ If your eyesight becomes impaired or if your eyes seem to be otherwise affected, consult an eye specialist immediately (see sections driving and<br />using machines and 4. Possible side effects).</p><p>□ Fluoroquinolone antibiotics may cause disturbances in blood sugar, including both a decrease in blood sugar below normal levels (hypoglycemia)<br />and an increase in blood sugar above normal levels (hyperglycemia). In patients treated with AVORES, disturbances in blood sugar occurred<br />predominantly in elderly patients receiving concomitant treatment with oral antidiabetic medicines that lower blood sugar (e. g. sulfonylurea) or with<br />insulin. If you suffer from diabetes, your blood sugar should be carefully monitored (see section 4. Possible side effects).<br />□ Quinolone antibiotics may make your skin become more sensitive to sunlight or UV light. You should avoid prolonged exposure to sunlight or strong<br />sunlight and should not use a sun bed or any other UV lamp while taking AVORES.<br />□ The efficacy of AVORES in the treatment of severe burns, infections of deep tissue and diabetic foot infections with osteomyelitis (infections of the<br />bone marrow) has not been established.<br />Children and adolescents<br />Do not give this medicine to children and adolescents under the age of 18 because efficacy and safety have not been established for this age group<br />(see section Do not take AVORES).<br />Taking other medicines with AVORES:<br />Tell your doctor or pharmacist about any other medicines that you are taking, took recently or might take.<br />For AVORES, be aware of the following:<br />□ If you are taking AVORES and other medicines that affect your heart there is an increased risk for altering your heart rhythm. Therefore, do not take<br />AVORES together with the following medicines:<br />- Medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide)<br />- Antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride) - Tricyclic antidepressants<br />- Some antimicrobials (e.g. saquinavir, sparfloxacin, intravenous erythromycin, pentamidine, antimalarials particularly halofantrine)<br />- Some antihistamines (e.g. terfenadine, astemizole, mizolastine)<br />- Other medicines (e.g. cisapride, intravenous vincamine, bepridil and diphemanil).<br />□ You must tell your doctor if you are taking other medicines that can lower your blood potassium levels (e.g. some diuretics, some laxatives and<br />enemas [high doses] or corticosteroids [anti-inflammatory drugs], amphotericin B) or cause a slow heart rate because these can also increase the risk<br />of serious heart rhythm disturbances while taking AVORES.<br />□ Any medicine containing magnesium or aluminium (such as antacids for indigestion), iron, zinc or didanosine or any medicine containing sucralfate<br />(to treat stomach disorders) can reduce the action of AVORES tablets. Take your AVORES tablet 6 hours before or after taking the other medicine.<br />□ Taking any medicine containing charcoal at the same time as AVORES tablets reduces the action of AVORES. It is recommended that these<br />medicines are not used together.<br />□ If you are currently taking drugs to thin your blood (oral anti-coagulants such as warfarin), it may be necessary for your doctor to monitor your blood<br />clotting time.</p><p>Taking AVORES with food and drink:<br />AVORES can be taken with or without food (including dairy products).<br />Pregnancy, breastfeeding and fertility:<br />Do not take AVORES if you are pregnant or breast-feeding.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine.<br />Animal studies do not indicate that your fertility will be impaired by taking this medicine.<br />Driving and using machines:<br />AVORES may make you feel dizzy or light-headed, you may experience a sudden, transient loss of vision, or you may faint for a short period. If you<br />are affected do not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />The recommended dose for adults is one 400mg film-coated tablet once daily.<br />AVORES tablets are for oral use. Swallow the tablet whole (to mask the bitter taste) and with plenty of liquid.<br />You can take AVORES with or without food. Try to take the tablet at approximately the same time each day.<br />The same dose can be taken by elderly patients, patients with a low bodyweight or in patients with kidney problems.<br />The time you will take AVORES for depends on your infection. Unless your doctor tells you otherwise, your treatment will be as follows:<br />□ For sudden worsening (acute exacerbation) of chronic bronchitis 5 - 10 days<br />□ For infection of the lungs (pneumonia) except for pneumonia which starts during a stay in hospital 10 days<br />□ For acute infection of the sinuses (acute bacterial sinusitis) 7 days<br />□ Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infection of the fallopian tubes and infection of<br />the uterus mucous membrane 14 days<br />When AVORES film-coated tablets are used to complete a course of therapy started with AVORES solution for infusion, the recommended durations<br />of use are:<br />□ Infection of the lungs (pneumonia) acquired outside the hospital 7 -14 days<br />- Most patients with pneumonia were switched to oral treatment with AVORES film-coated tablets within 4 days<br />□ Infections of the skin and soft tissue 7 -21 days<br />Most patients with infections of the skin and soft tissue were switched to oral treatment with AVORES film-coated tablets within 6 days.<br />It is important that you complete the course of treatment even if you begin to feel better after a few days. If you stop taking AVORES too soon your<br />infection may not be completely cured and the infection may return or your condition may get worse. The bacteria causing your infection may become<br />resistant to AVORES.<br />The recommended dose and duration of treatment should not be exceeded (see section 2. Before you take AVORES, Take special care with<br />AVORES).<br />If you take more AVORES than you should:<br />If you take more than the prescribed one tablet a day, get medical help immediately. Try to take any remaining tablets, the packaging or this leaflet<br />with you to show the doctor or pharmacist what you have taken.<br />If you forget to take AVORES:<br />If you forget to take your tablet you should take it as soon as you remember on the same day. If you do not remember on the same day, take your<br />normal dose (one tablet) on the next day. Do not take a double dose to make up for a forgotten dose. If you are unsure about what to do ask your<br />doctor or pharmacist.<br />If you stop taking AVORES:<br />If you stop taking this medicine too soon your infection may not be completely cured. Talk to your doctor if you wish to stop taking your tablets before<br />the end of the course of treatment. If you have any further questions about this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The most serious side effects observed during treatment with Moxifloxacin are listed below:<br />If you notice<br />□ An abnormal fast heart rhythm (rare side effect) □ That you suddenly start feeling unwell or notice yellowing of the whites of the eyes, dark urine,<br />itching of the skin, a tendency to bleed or disturbances of thought or wakefulness (these can be signs and symptoms of fulminant inflammation of the<br />liver potentially leading to life-threating liver failure (very rare side effect, fatal cases have been observed))<br />□ Alterations of the skin and mucous membranes like painful blisters in the mouth/nose or at the penis/vagina (Stevens-Johnson syndrome or toxic<br />epidermal necrolysis) (very rare side effects, potentially life threatening)<br />□ Inflammation of blood vessels (signs could be red spots on your skin, usually on your lower legs or effects like joint pain) (very rare side effect)<br />□ A severe, sudden generalised allergic reaction incl. very rarely a life-threatening shock (e.g. difficulty in breathing, drop of blood pressure, fast pulse)</p><p>(rare side effect) □ Swelling incl. swelling of the airway (rare side effect, potentially life-threatening) □ Convulsions (rare side effect)<br />□ Troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities (rare side effect)<br />□ Depression (in very rare cases leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (rare side effect)<br />□ Insanity (potentially leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (very rare side effect)<br />□ Severe diarrhoea containing blood and/or mucus (antibiotic associated colitis incl. pseudomembranous colitis), which in very rare circumstances,<br />may develop into complications that are life-threatening (rare side effects)<br />□ Pain and swelling of the tendons (tendonitis) (rare side effect) or a tendon rupture (very rare side effect)<br />Stop taking AVORES and tell your doctor immediately as you may need urgent medical advice.<br />In addition, if you notice:<br />□ Transient loss of vision (very rare side effect), contact an eye specialist immediately.<br />□ If you have experienced life-threatening irregular heart beat (Torsade de Pointes) or stopping of heart beat while taking AVORES (very rare side<br />effects), tell your treating doctor immediately that you have taken AVORES and do not restart the treatment.<br />□ A woresning of the symptoms of myasthenia gravis has been observed in very rare cases. if this happens, consult your doctor immediately.<br />□ If you suffer from diabetes and you notice that your blood sugar is increased or decreased (rare or very rare side effect), inform your doctor<br />immediately.<br />□ If you are elderly with existing kidney problems and you notice decrease in urine output, swelling in your legs, ankles or feet, fatigue, nausea,<br />drowsiness, shortness of breath or confusion (these can be signs and symptoms of kidney failure, a rare side effect), consult your doctor<br />immediately.<br />Other side effects which have been observed during treatment with AVORES are listed below by how likely they are:<br />Common (may affect up to 1 in 10 people): □ Nausea □ Diarrhoea □ Dizziness □ Stomach and abdominal ache □ Vomiting<br />□ Headache □ Increase of a special liver enzyme in the blood (transaminases) □ Infections caused by resistant bacteria or fungi e.g. oral and<br />vaginal infections caused by Candida □ Change of the heart rhythm (ECG) in patients with low blood potassium level<br />Uncommon (may affect up to 1 in 100 people): □ Rash □ Stomach upset (indigestion/heartburn) □ Changes in taste (in very rare cases loss<br />of taste) □ Sleep problems (predominantly sleeplessness) □ Increase of a special liver enzyme in the blood (gamma-glutamyl-transferase and/or<br />alkaline phosphatase) □ Low number of special white blood cells (leukocytes, neutrophils) □ Constipation □ Itching □ Sensation of dizziness<br />(spinning or falling over) □ Sleepiness □ Wind □ Change of the heart rhythm (ECG) □ Impaired liver function (incl. increase of a special liver<br />enzyme in the blood (LDH)) □ Decreased appetite and food intake □ Low white blood cells count □ Aches and pains such as back, chest, pelvic<br />and extremities pains □ Increase of special blood cells necessary for blood clotting □ Sweating □ Increased specialised white blood cells<br />(eosinophils) □ Anxiety □ Feeling unwell (predomin antly weakness or tiredness) □ Shaking □ Joint pain □ Palpitations □ Irregular and fast heart<br />beat □ Difficulty in breathing incl. asthmatic conditions □ Increase of a special digestive enzyme in the blood (amylase) □ Restlessness / agitation<br />□ Tingling sensation (pins and needles) and/or numbness □ Skin hives □ Widening of blood vessels □ Confusion and disorientation □ Decrease of<br />special blood cells necessary for blood clotting □ Visual disturbances incl. double and blurred vision □ Decreased blood clotting □ Increased blood<br />lipids (fats) □ Low red blood cell count □ Muscle pain □ Allergic reaction □ Increase of bilirubin in the blood □ Inflammation of the stomach<br />□ Dehydration □ Severe heart rhythm abnormalities □ Dry skin □ Angina pectoris<br />Rare (may affect up to 1 in 1,000 people): □ Muscle twitching □ Muscle cramp □ Hallucination □ High blood pressure □ Swelling (of the hands,<br />feet, ankles, lips, mouth, throat) □ Low blood pressure □ Kidney impairment (incl. increase in special kidney laboratory test results like urea and<br />creatinine) □ Inflammation of the liver □ Inflammation of the mouth □ Ringing/noise in the ears □ Jaundice (yellowing of the whites of the eyes or<br />skin) □ Impairment of skin sensation □ Abnormal dreams □ Disturbed concentration □ Difficulty in swallowing □ Changes in smell (incl. loss of<br />smell) □ Balance disorder and poor co-ordination (due to dizziness) □ Partial or total loss of memory □ Hearing impairment including deafness<br />(usually reversible) □ Increased blood uric acid □ Emotional instability □ Impaired speech □ Fainting □ Muscle weakness.<br />Very rare (may affect up to 1 in 10,000 people): □ Inflammation of joints □ Abnormal heart rhythms □ Increase of skin sensitivity<br />□ A feeling of self-detachment (not being yourself) □ Increased blood clotting □ Muscle rigidity □ Significant decrease of special white blood cells<br />(agranulocytosis)<br />Also, there have been very rare cases of the following side effects reported following treatment with other quinolone antibiotics, which might<br />possibly also occur during treatment with AVORES:<br />□ Increased blood sodium levels □ Increased blood calcium levels □ A special type of reduced red blood cell count (haemolytic anaemia)<br />□ Muscle reactions with muscle cell damage □ Increased sensitivity of the skin to sunlight or UV light.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ Keep out of the reach and sight of children.<br />□ Do not store above 30&deg;C.<br />□ Do not use AVORES after the expiry date which is stated on the carton and on the blister, after (EXP).Date.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.<br />These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ The active substance is Moxifloxacin. Each Film Coated Tablet contains Moxifloxacin 400 mg as Moxifloxacin Hydrochloride.<br />□ The other ingredients are: microcrystalline cellulose, mannitol spray dried, sodium starch glycolate type A, colloidal anhydrous silica, magnesium<br />stearate, opadry II 33G24737 pink, white beeswax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                □ AVORES 400 mg tablets are dull red shallow biconvex oblong film coated tablets debossed with “MX4” one side and plain on the other.
□ Boxes of 5 blistered tablets of AVORES 400.
□ Boxes of 7 blistered tablets of AVORES 400.
Saudi Arabia: To report any side effect(s): National Pharmacovigilance and Drug Safety Center (NPC): call NPC at +966-11-2038222, Exts: 2317-
2356 - 2353 - 2354 - 2334 - 2340, Fax: +966-11-205-7662, Toll - free: 8002490000, E-mail: npc.drug@sfda.gov.sa
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian Pharmaceutical Manufacturing Company&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي أڤورس على المادة الفعالة موكسيفلوكساسين وهو ينتمي إلى مجموعة المضادات الحيوية التي تدعى فلوروكوينولونات. يعمل أڤورس على قتل البكتيريا التي تسبب العدوى. يستخدم أڤورس لدى<br />المرضى الذين تتراوح أعمارهم ما بين ۱۸ سنة وما فوق لمعالجة العدوى البكتيرية التالية و التي يكون موكسيفلوكساسين فعال ضدها. يستخدم أڤورس لمعالجة هذه العدوى في حال أن المضادات الحيوية<br />الاعتيادية لا يمكن استخدامها أو أنها تكون غير فعالة:<br />عدوى الجيوب الأنفية، التفاقم المفاجئ لالتهاب الشعب الهوائية طويل الأمد أو الالتهاب الرئوي المكتسب خارج المستشفى (ما عدا الحالات الخطيرة). □<br />عدوى المسالك التناسلية العليا للإناث التي تكون خفيفة إلى معتدلة (التهاب الحوض) والتي تشمل عدوى قناة فالوب وعدوى الغشاء المخاطي للرحم. أقراص أڤورس وحدها لا تكون كافية لمعالجة هذه □<br />العدوى، لذلك سيصف لك طبيبك مضادات حيوية أخرى بالإضافة إلى أڤورس لمعالجة عدوى المسالك التناسلية العليا لدى الإناث (انظر قسم ۲ قبل القيام بتناول أو استعمال أڤورس، الاحتياطات عند<br />استعمال أڤورس، أخبر طبيبك قبل تناول أڤورس).<br />إذا أظهرت العدوى البكتيرية التالية تحسناً خلال المعالجة الأولية باستخدام محلول أڤورس المعطى عبر الوريد فإن أقراص أڤورس قد توصف أيضاً من قبل الطبيب لإكمال المدة المحددة للعلاج: الالتهاب<br />الرئوي المكتسب خارج المستشفى، عدوى الجلد والأنسجة الرخوة. لا يجب استخدام أقراص أڤورس لوحدها لبدء معالجة أي نوع من أنواع عدوى الجلد والأنسجة الرخوة أو الالتهاب الرئوي الخطير</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اتصل بطبيبك إذا لم تكن متأكد إلى أي مجموعة من مجموعات المرضى التالية تنتمي.<br />موانع استعمال أڤورس:<br />.( إذا كنت تعاني من الحساسية للمادة الفعالة موكسيفلوكساسين أو للمضادات الحيوية التي تنتمي إلى مجموعة كينولون أو لأي من مكونات الدواء الأخرى (المدرجة في قسم ٦ □<br />إذا كنت حاملاً أو مرضعة. □<br />إذا كان عمرك أقل من ۱۸ سنة. □<br />إذا عانيت مسبقاً من مشاكل في الأوتار المتعلقة باستخدام المضادات الحيوية التي تنتمي إلى مجموعة كينولون (انظر إلى قسم الاحتياطات عند استعمال أڤورس وقسم ٤ الأعراض الجانبية). □<br />إذا كنت قد ولدت مع أو لديك: □<br />- أي حالة مرضية مع عدم انتظام في ضربات القلب (الموجودة على مخطط كهربية القلب، التسجيل الكهريائي للقلب) - اختلال توازن الأملاح في الدم (وخاصة انخفاض مستويات البوتاسيوم والمغنيزيوم<br />في الدم) - بطء شديد في ضربات القلب - فشل القلب - تاريخ في عدم انتظام ضربات القلب - أو إذا كنت تتناول أدوية أخرى تؤدي إلى تغيرات غير طبيعية في مخطط كهربية القلب (انظر إلى<br />أي تأخر توصيل الاشارات الكهربائية. QT قسم نتاول أڤورس مع أدوية أخرى)، وذلك لأن أڤورس قد يسبب تغيرات في مخطط كهربية القلب وهو إطالة فترة<br />إذا كنت تعاني من مرض خطير في الكبد أو زيادة في أنزيمات الكبد (ناقلات الأمين) التي تكون أعلى بخمسة أضعاف من الحد الطبيعي العلوي. □<br />الاحتياطات عند استعمال أڤورس:<br />تحدث مع طبيبك قبل تناول أڤورس:<br />يمكن أن يؤدي أڤورس إلى تغييرفي مخطط كهربية القلب وخاصة لدى الإناث و المسنين. إذا كنت حالياً تتناول أي دواء يؤدي إلى انخفاض مستوى البوتاسيوم في الدم فإن عليك استشارة الطبيب قبل □<br />تناول أڤورس (انظر أيضاً إلى قسم موانع استعمال أڤورس و تناول أڤورس مع أدوية أخرى).<br />تحدث مع طبيبك قبل تناول أڤورس إذا كنت تعاني من الصرع أو من حالة مرضية تجعلك عرضة للإصابة باختلاجات. □<br />استشر طبيبك قبل تناول أڤورس إذا كنت تعاني من مشاكل نفسية. □<br />إذا كنت تعاني من الوهن العضلي الوبيل (تعب غير طبيعي في العضلات يؤدي في الحالات الخطيرة إلى حدوث شلل) فإن تناول أڤورس قد يؤدي إلى تفاقم أعراض هذا المرض. استشر طبيبك مباشرة □<br />إذا كنت تعتقد بأنك تعاني من تفاقم في الأعراض.<br />إذا كنت تعاني أنت أو أي فرد من أفراد عائلتك من نقص نازعة هيدروجين الغلوكوز - ٦- فسفات (مرض وراثي نادر) فإن عليك أن تستشير طبيبك ليخبرك إذا كان من المناسب لك أن تستخدم أڤورس. □<br />إذا كنت تعاني من عدوى مصحوبة بمضاعفات في المسالك التناسلية العلوية للإناث (على سبيل المثال حدوث خراج في قناة فالوب والمبيضين أو الحوض) في هذه الحالة قد يصف الطبيب معالجة عن □<br />طريق الوريد لأن المعالجة عن طريق استخدام أقراص أڤورس لا تكون مناسبة.<br />لمعالجة عدوى المسالك التناسلية العلوية للإناث الخفيفة والمتوسطة فإن طبيبك قد يصف لك مضاداً حيوياً آخر بالإضافة إلى أڤورس. استشر طبيبك إذا لم يحدث تحسن في الأعراض خلال ۳ أيام من □<br />المعالجة.<br />عند تناول أڤورس:<br />يجب عليك إبلاغ الطبيب على الفور إذا حدث معك خفقان في القلب أو عدم انتظام في ضربات القلب خلال فترة المعالجة، فقد يرغب طبيبك في إجراء مخطط لكهربية القلب لقياس ضربات القلب لديك. □<br />قد يزداد خطر المشاكل القلبية مع زيادة الجرعة، لذلك ينبغي اتباع الجرعة الموصى بها. □<br />قد تواجه فرصة نادرة لحدوث تفاعل تحسسي خطير ومفاجئ (تفاعل تأقي) حتى بعد تلقي الجرعة الأولى، ويشمل الأعراض التالية: ضيق في الصدر، الشعور بالدوار، الشعور بالغثيان أو الإصابة □<br />بالإغماء، دوخة عند الوقوف، فإذا حدث لك ذلك، فإنه يجب عليك التوقف عن تناول أڤورس وطلب المشورة الطبية على الفور.<br />قد يؤدي أڤورس إلى حدوث التهاب سريع وحاد في الكبد والذي قد يؤدي إلى فشل كبدي مهدد للحياة (ويشمل حالات قاتلة، انظر إلى قسم ٤، الأعراض الجانبية). يرجى استشارة الطبيب قبل تناول المزيد □<br />من الأقراص إذا شعرت بشكل مفاجئ بتوعك وكان لديك أيضاً اصفرار في بياض العين أو بول داكن أو حكة في الجلد أو قابلية للنزف أو مرض دماغي محرض من الكبد (أعراض لانخفاض وظيفة الكبد<br />أو أعراض التهاب سريع وحاد في الكبد).<br />اتصل بطبيبك على الفور قبل الاستمرار بالمعالجة إذا أصبت بتفاعل جلدي أو تقرحات جلدية / تقشر في الجلد و/أو تفاعل في الأغشية المخاطية (انظر إلى قسم ٤، الأعراض الجانبية). □<br />قد تؤدي المضادات الحيوية للكينولون بما في ذلك أڤورس إلى حدوث اختلاجات. فإذا حدث لك ذلك، فإنه يجب عليك التوقف عن تناول أڤورس والاتصال بطيبيك على الفور. □<br />قد تتعرض للإصابة بأعراض الاعتلال العصبي مثل، الألم و/أو الشعور بالحرق و/أو وخز و/أو خدر و/أو ضعف خاصة في الأقداو و الأرجل أو الأيدي و الأذرع. ، فإذا حدث لك ذلك، فإنه يجب عليك □<br />إخبار طبيبك على الفور قبل استمرارالعلاج باستخدام أڤورس.<br />قد تتعرض لمشاكل نفسية عند استخدام المضادات الحيوية للكينولون بما في ذلك أڤورس حتى عند الاستخدام للمرة الأولى. في حالات نادرة جداً، قد يؤدي الاكتئاب والمشاكل النفسية إلى أفكار انتحارية و □<br />سلوكيات مضرة بالنفس مثل محاولات الانتحار (انظر إلى قسم ٤، الأعراض الجانبية). فإذا حدثت لك مثل هذه التفاعلات، فإنه يجب عليك التوقف عن تناول أڤورس وإخبار طبيبك على الفور.<br />قد تتعرض للإصابة بالإسهال أثناء أو بعد تناول المضادات الحيوية بما في ذلك أڤورس، فإذا أصبحت حالة الإسهال شديدة أو مستمرة أو إذا لاحظت وجود دم أو مخاط في البراز فإنه يجب عليك التوقف □<br />عن تناول أڤورس واستشارة طبيبك على الفور. لا يجب أن تتناول أدوية تعمل على إيقاف أو إبطاء حركة الامعاء.<br />قد يؤدي أڤورس إلى آلام والتهاب الأوتار حتى في غضون ٤۸ ساعة من بدء المعالجة ولعدة أشهر بعد وقف المعالجة باستخدام أڤورس. تزداد خطورة التهاب وتمزق الأوتار إذا كنت من المسنيين أو إذا □<br />كنت تتناول أدوية الكورتيكوستيرويد. عند ظهور أول علامة للألم أو للالتهاب فإنه يجب عليك التوقف عن تناول أڤورس وإراحة الطرف المصاب واستشارة طبيبك على الفور. ويجب تجنب أي ممارسة<br />غير ضرورية لأن ذلك قد يؤدي إلى زيادة تمزق الأوتار (انظر إلى قسم موانع استعمال أڤورس و قسم ٤، الأعراض الجانبية).<br />إذا كنت من المسنيين وتعاني من مشاكل في الكلى فإنه يجب أن تتأكد من أنك تشرب كمية كافية من الماء عند تناول أڤورس. إذا كان لديك جفاف فإن ذلك يؤدي إلى حدوث فشل كلوي. □<br />إذا أصبح بصرك ضعيف أو إذا لاحظت تأثيرعلى عينيك أثناء تناول أڤورس، فإنه يجب استشارة الطبيب المتخصص في العيون على الفور (انظر إلى قسم تأثير المستحضرعلى القيادة واستخدام الآلات □<br />وقسم ٤، الأعراض الجانبية).<br />قد يؤدي استخدام مضادات الفلوروكوينولون إلى خلل في مستوى السكر في الدم وذلك يشمل انخفاض نسبة السكر تحت المستوى الطبيعي و ارتفاع نسبة السكر فوق المستوى الطبيعي. حدث خلل في في&nbsp;مستوى السكر لدى المرضى كبار السن على الأغلب والذين يتعالجون باستخدام موكسيفلوكساسين بالتزامن مع الأدوية الفموية المضادة للسكري والتي تؤدي إلى خفض مستوى السكر في الدم (مثل،<br />سلفونيل يوريا) أو الأنسولين. إذا كنت تعاني من مرض السكري فإنه يجب مراقبة نسبة السكري في الدم بعناية (انظر إلى قسم ٤. الأعراض الجانبية)<br />قد يؤدي استخدام المضادات الحيوية للكينولون إلى زيادة حساسية الجلد لأشعة الشمس أو للأشعة فوق البنفسجية، لذلك يجب عليك تجنب التعرض لأشعة الشمس لفترة طويلة أو التعرض لأشعة الشمس □<br />القوية ويجب عدم استخدام أجهزة دباغة الجلد أو أي مصباح للأشعة فوق البنفسجية أثناء تناول أڤورس.<br />لم تثبت فعالية أڤورس في علاج الحروق الشديدة وعدوى الأنسجة العميقة وعدوى القدم السكرية مع التهاب العظم والنقي (عدوى نخاع العظم). □<br />الأطفال والمراهقين:<br />لا يعطى هذا الدواء للأطفال والمراهقين دون سن ۱۸ سنة، لأنه لم يتم إثبات فعالية ومأمونية هذا الدواء على هذه الفئة العمرية (انظر إلى قسم موانع استعمال أڤورس).<br />تناول أڤورس مع الأدوية أخرى:<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية.<br />عند استخدام أڤورس يجب أن تكون على علم بما يلي:<br />هنالك خطر متزايد على حدوث تغيير نظم القلب في حالة أخذ أڤورس مع أدوية أخرى لها تأثير على القلب، لذلك لا تأخذ أڤورس مع الأدوية التالية: □<br />- الأدوية التي تنتمي إلى مجموعة مضادات اضطراب نظم القلب (مثل، كينيدين، هيدروكينيدين، ديسوبيرامايد، أميودارون، سوتالول، دوفيتيلايد، أيبوتيلايد)<br />- مضادات الذهان (مثل، فينوثيازين، بيموزايد، سرتيندول، هالوبيريدول، سلتوبرايد)<br />- مضادات الاكتئاب ثلاثية الحلقات<br />- مضادات المكروبات (مثل، ساكوينافير، سبارفلوكساسين، إيرثرومايسين معطى عن طريق الوريد، بنتاميدين، مضادات الملاريا وخاصة هالوفانترين)<br />- بعض مضادات الهستامين (مثل، تيرفينادين، استيميزول، ميزولاستين)<br />- أدوية أخرى (مثل، سيسابرايد، فينكامين المعطى عن طريق الوريد، بيبريديل و ديفيمانيل).<br />يجب إخبار طبيبك إذا كنت تتناول أدوية تعمل على خفض مستويات البوتاسيوم في الدم (مثل، بعض مدرات البول، بعض الملينات و الحقن الشرجية (جرعات عالية) أو الكورتيكوستيرويدات (الأدوية □<br />المضادة للالتهاب)، الأمفوتريسين ب) أو الأدوية التي تسبب بطء في ضربات القلب لأن هذه الأدوية أيضاً تزيد من خطر حدوث اضطرابات خطيرة في نظم القلب أثناء تناول أڤورس.<br />أي أدوية تحتوي على مغنيزيوم أو ألمينيوم (مثل مضادات الحموضة لعلاج عسر الهضم)، حديد أو زنك أو ديدانوزين أو أي دواء يحتوي على سكرالفيت (لمعالجة اضطرابات المعدة) حيث أن هذه □<br />الأدوية يمكن أن تقلل من مفعول أقراص أڤورس. تناول أقراص أڤورس قبل أو بعد ٦ ساعات من تناول أي دواء آخر.<br />تناول أي دواء يحتوي على فحم في نفس وقت تناول أقراص أڤورس يؤدي إلى تقليل مفعول أڤورس. ينصح بعدم استخدام هذه الأدوية معاً. □<br />قد يكون من الضروري لطبيبك بأن يراقب وقت تخثر الدم لديك إذا كنت تتناول أدوية تعمل على تميع الدم (مضادات التخثر مثل وارفارين). □<br />تناول أڤورس مع الطعام والشراب:<br />يمكن تناول أڤورس مع أو بدون الطعام (بما في ذلك منتجات الألبان).<br />الحمل والرضاعة:<br />لا تتناولي أڤورس إذا كنت حاملاً أو مرضعة.<br />اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء إذا كنت حاملاً أو مرضعة أو إذا كان لديك رغبة في الإنجاب.<br />لم تدل الدراسات على الحيوانات بأن الخصوبة تضعف عند استخدام هذا الدواء.<br />تأثير المستحضر على القيادة واستخدام الآلات:<br />قد يسبب لك أڤورس الشعور بالدوار أو الدوخة وقد تواجه فقدان في الرؤية بصورة مفاجئة وعابرة أو قد يغمى عليك لفترة قصيرة. إذا واجهت مثل هذه الأعراض فإنه يجب عليك أن لا تقود أو تشغل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب أن تتناول أڤورس كما أخبرك طبيبك أو الصيدلي تماماً. يجب عليك مراجعة الطبيب أو الصيدلي إذا كنت غير متأكد.<br />الجرعة الموصى بها للبالغين هي قرص مغلف واحد ٤۰۰ ملغم يومياً.<br />تستخدم أقراص أڤورس عن طريق الفم. ابتلع القرص بأكمله (لإخفاء الطعم المر) مع كمية كافية من السوائل.<br />يمكن تناول أڤورس مع الطعام أو بدونه. حاول أن تتناول القرص في نفس الوقت من كل يوم.<br />يمكن أن تؤخذ نفس الجرعة من قبل المرضى المسنين، أو المرضى الذين يعانون من انخفاض وزن الجسم أو المرضى الذين يعانون من مشاكل في الكلى.<br />تعتمد المدة التي ستتناول خلالها أڤورس على شدة العدوى لديك، وسيكون العلاج على النحو التالي مالم يخبرك طبيبك بخلاف ذلك:<br />التفاقم المفاجئ لالتهابات الشعب الهوائية المزمن (تفاقم حاد) مدة العلاج ٥ إلى ۱۰ أيام □<br />الالتهاب الرئوي، باستثناء الالتهاب الرئوي المكتسب خلال الإقامة في المستشفى مدة العلاج ۱۰ أيام □<br />عدوى الجيوب الأنفية الحادة مدة العلاج ۷ أيام □<br />عدوى المسالك التناسلية العليا للإناث التي تكون خفيفة إلى معتدلة (مرض التهاب الحوض) والتي تشمل عدوى قناة فالوب وعدوى الغشاء المخاطي للرحم مدة العلاج ۱٤ يوم □<br />عند استخدام أقراص أڤورس المغلفة لإكمال المدة المحددة للعلاج الذي بدأ باستخدام محلول موكسيفلوكساسين للحقن (التسريب)، فإن المدة العلاجية تكون على النحو التالي:<br />الالتهاب الرئوي المكتسب خارج المستشفى مدة العلاج ۷ إلى ۱٤ يوم □<br />تم تحويل معظم المرضى الذين يعانون من الالتهاب الرئوي الى المعالجة باستخدام أقراص أڤورس المغلفة خلال ٤ أيام.<br />عدوى الجلد والأنسجة الرخوة مدة العلاج ۷ إلى ۲۱ □<br />تم تحويل معظم المرضى الذين يعانون من عدوى الجلد والأنسجة الرخوة الى المعالجة باستخدام أقراص أڤورس المغلفة خلال ٦ أيام.<br />من المهم إكمال المدة المحددة للعلاج حتى لو بدأت بالشعور بتحسن بعد بضعة أيام من المعالجة. إذا توقفت عن تناول أڤورس خلال وقت قريب من المدة المقررة للعلاج فإن ذلك قد يؤدي إلى عدم علاج<br />العدوى بشكل كامل وقد تعود مرة أخرى أو تتفاقم. قد تصبح البكتيريا المسببة للعدوى مقاومة لأڤورس.<br />يجب أن لا يتم تجاوز الجرعة ومدة العلاج الموصى بها (انظر إلى قسم ۲، قبل القيام بتناول أو استعمال أڤورس، الاحتياطات عند استعمال أڤورس).<br />الجرعة الزائدة من أڤورس:<br />يجب عليك طلب المساعدة الطبية على الفور إذا كنت قد تناولت أكثر من الجرعة الموصوفة لك والتي هي قرص واحد يومياً. حاول أن تأخذ الأقراص المتبقية أو علبة الدواء أو هذه النشرة معك وإعطاؤها<br />للطبيب أو الصيدلي لمعرفة الأقراص التي قد تناولتها.<br />نسيان تناول جرعة أڤورس:<br />إذا كنت قد نسيت أن تأخذ الجرعة المقررة لك (قرص واحد)، فإنه يجب عليك أن تأخذها في أقرب وقت ممكن من تذكرها في نفس اليوم. إذا نسيت أن تتناول الجرعة في نفس اليوم، فإنه يجب عليك أن<br />تاخذ الجرعة الاعتيادية (قرص واحد) في اليوم التالي. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.<br />إذا كنت غير متأكد حول ما يجب فعله فإنه يجب عليك أن تسال طبيبك أو الصيدلي.<br />التوقف عن تناول أڤورس:<br />إذا توقفت عن تناول أڤورس خلال وقت قريب من المدة المقررة للعلاج فإن ذلك قد يؤدي إلى عدم علاج العدوى بشكل كامل. تحدث إلى طبيبك إذا كنت ترغب في التوقف عن تناول الأقراص قبل إكمال<br />المدة المحددة للعلاج.<br />اسأل طبيبك أو الصيدلي، إذا كان لديك أي أسئلة أخرى حول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، فإن أڤورس قد يسبب آعراضاً جانبية، بالرغم من أنها لاتحدث للجميع.<br />الأعراض الجانبية الأكثر خطورة والتي لوحظت أثناء المعالجة باستخدام موكسيفلوكساسين مذكورة أدناه:<br />شعرت بشكل مفاجئ بتوعك أو لاحظت اصفرار في بياض العين، بول داكن، حكة في الجلد، قابلية للنزف أو اضطرابات فكرية أو □ ( نظم قلب غير طبيعي وسريع (عرض جانبي نادر □ : إذا لاحظت&nbsp;أرق (يمكن أن تكون هذه علامات وأعراض لالتهاب مداهم للكبد والذي قد يؤدي إلى فشل كبدي مهدد للحياة) (عرض جانبي نادر جداً، لوحظت حالات وفاة<br />التهاب الأوعية الدموية □ ( تقرحات مؤلمة في الفم/ الأنف أو القضيب / المهبل (متلازمة ستيفنز جونسون أو تقشر الأنسجة المتموتة البشروية التسممي) (أعراض جانبية نادرة، من المحتمل أن تهدد الحياة<br />تفاعل تحسسي عام مفاجئ وشديد يشمل صدمة مهددة للحياة ونادرة □ ( (قد تتمثل العلامات ببقع حمراء على جلدك، عادة ما تكون في أسفل الأرجل أو آثار مثل ألم المفاصل) ( أعراض جانبية نادرة جداً<br />اختلاجات (عرض □ ( تورم والذي يشمل تورم الشعب الهوائية (عرض جانبي نادر، من المحتمل أن يهدد الحياة □ ( جداً (صعوبة في التنفس، انخفاض في ضغط الدم، نبض سريع) (عرض جانبي نادر<br />اكتئاب (في حالات نادرة قد يؤدي إلى إيذاءالنفس مثل أفكار انتحارية □ ( مشاكل مرتبطة بالجهاز العصبي مثل الألم، الحرقان، وخز، خدر و/أو ضعف في الأطراف (عرض جانبي نادر □ ( جانبي نادر<br />إسهال شديد يحتوي على دم و/أو مخاط □ ( الجنون (من المحتمل أن تؤدي إلى إيذاء النفس مثل أفكار انتحارية أو محاولات انتحار) (عرض جانبي نادر جداً □ ( أو محاولات انتحار) (عرض جانبي نادر<br />(التهاب القولون المرتبط باستخدام المضادات الحيوية وذلك يشمل التهاب القولون الغشائي الكاذب) والذي في حالات نادرة جداً قد يؤدي إلى حدوث مضاعفات مهددة للحياة (أعراض جانبية نادرة)<br />ألم وتورم الأوتار (التهاب الأوتار) (عرض جانبي نادر) أو تمزق الأوتار (عرض جانبي نادر جداً). □<br />توقف عن تناول أڤورس وأخبر طبيبك مباشرة لأنك قد تحتاج إلى المشورة الطبية العاجلة:<br />أو (Torsade de Pointes) إذا واجهت ضربات قلب غير منتظمة ومهددة للحياة □ فقدان مؤقت للرؤية (عرض جانبي نادر جداً). اتصل بأخصائي للعيون مباشرة □ : بالإضافة إلى ذلك إذا لاحظت<br />تم ملاحظة تفاقم في أعراض الوهن □ توقف ضربات القلب أثناء تناول أڤورس (عرض جانبي نادر جداً)، فإن عليك إخبار طبيبك المعالج مباشرة بأنك كنت تتناول أڤورس، ولا تقوم بإعادة العلاج<br />العضلي لدى حالات نادرة جداً، استشر طبيبك مباشرة في حال حدوث ذلك.<br />إذا كنت تعاني من مرض السكري ولاحظت زيادة أو انخفاض في مستوى سكر الدم (عرض جانبي نادر أو نادر جداً) فإن عليك إخبار طبيبك مباشرة. □<br />إذا كنت من كبار السن وتعاني من مشاكل في الكلى ولاحظت انخفاض في كمية البول، وتورم في الساقين أو الكاحلين أو القدمين، تعب، غثيان، نعاس، ضيق في التنفس أو ارتباك (قد تكون هذه □<br />علامات وأعراض لفشل كلوي، عرض جانبي نادر) فإن عليك استشارة طبيبك مباشرة.<br />الأعراض الجانبية الأخرى التي لوحظت أثناء المعالجة باستخدام أڤورس مذكورة أدناة حسب احنمال حدوثها:<br />التهبات □ ( زيادة انزيم الكبد الخاص في الدم (الترانساميناسات □ صداع □ قيء □ ألم في المعدة والبطن □ دوخة □ إسهال □ غثيان □ :( شائعة (تؤثر على شخص واحد من بين ۱۰ أشخاص<br />تغير في نظم القلب لدى المرضى الذين يعانون من انخفاض في مستويات البوتاسيوم في الدم. □ ناجمة عن البكتيريا المقاومة أو الفطريات مثل التهابات الفم أو المهبل الناجمة عن المبيضات<br />مشاكل في النوم □ ( تغيرات في التذوق (في حالات نادرة فقدان التذوق □ ( اضطراب في المعدة (عسر هضم/ قرحة معدة □ طفح جلدي □ :( غير شائعة (تؤثر على شخص واحد من بين ۱۰۰ شخص<br />انخفاض عدد خلايا دم بيضاء معينة (الكريات □ ( مشاكل في النوم (أرق في الغالب) ارتفاع نسبة أنزيم كبدي معين في الدم (ناقلات الأمين غاما-غلوتاميل و/أو الفوسفاتيز القلوي □ ( (أرق في الغالب<br />تغير نظم القلب □ ريح □ النعاس □ ( الشعور بالدوخة (الدوار أو السقوط □ حكة □ إمساك □ ( البيض، العدلات<br />انخفاض عدد خلايا الدم البيضاء □ انخفاض الشهية والرغبة في تناول الطعام □ (LDH) فشل وظيفة الكبد (تشمل ارتفاع نسبة أنزيم كبدي معين في الدم □<br />الشعور بالتوعك □ قلق □ ( ارتفاع خلايا دم بيضاء معينة (الخلايا اليوزينية □ تعرق □ ارتفاع خلايا معينة في الدم لازمة لتخثر الدم □ أوجاع وألام مثل ألم الظهر والصدر والحوض والأطراف □<br />أرق/ □ ( ارتفاع أنزيم هضم معين في الدم (الأميليز □ صعوبة في التنفس تشمل حالات الربو □ ضربات قلب سريعة وغير منتظمة □ ألم في المفاصل □ اهتزاز □ ( (على الأغلب ضعف وتعب<br />اضطراب في الرؤية يشمل ازدواج وعدم وضوح الرؤية □ انخفاض خلايا معينة لازمة لتخثر الدم □ ارتباك وتوهان □ توسع الأوعية الدموية □ شرى □ الشعور بوخز و/أو خدر □ هيجان<br />جفاف □ التهاب في المعدة □ ارتفاع مستوى البيليروبين في الدم □ تفاعلات تحسسية □ ألم في العضلات □ انخفاض عدد خلايا الدم الحمراء □ ارتفاع مستويات الدهون في الدم □ انخفاض تخثر الدم □<br />الذبحة الصدرية □ جفاف الجلد □ خلل شديد في نظم القلب □<br />انخفاض □ تورم اليدين، القدمين، الكاحلين، الشفاه، الفم، الحلق □ ارتفاع ضغط الدم □ هلوسة □ تشنج العضلات □ ارتعاش العضلات □ :( نادرة (تؤثر على شخص واحد من بين ۱۰۰۰ شخص<br />يرقان (اصفرار بياض العينين أو □ رنين/ ضجيج في الأذنين □ التهاب الفم □ التهاب الكبد □ ( فشل كلوي (يشمل ارتفاع نتائج معينة لفحوصات الكلى المخبرية مثل اليوريا والكرياتينين □ ضغط الدم<br />اضطراب التوازن و عدم القدرة على تناسق الحركة □ ( تغيرات في حاسة الشم (يشمل فقدا ن حاسة الشم □ صعوبة البلع □ خلل في التركيز □ أحلام غير طبيعية □ انخفاض الإحساس الجلدي □ الجلد<br />إعاقة النطق □ عدم الاستقرار العاطفي □ ارتفاع مستوى حمض اليوريك في الدم □ ( فشل السمع والذي يشمل الصمم (يكون عادة قابل للتراجع □ فقدان جزئي أو كلي في الذاكرة □ ( (بسبب الدوخة<br />ضعف العضلات □ إغماء □<br />زيادة تخثر الد م □ الشعور بانفصال الذات □ زيادة حساسية الجلد □ تظم قلب غير طبيعي □ التهاب المفاصل □ :( نادرة جداً (تؤثر على شخص واحد من بين ۱۰۰۰۰ شخص<br />انخفاض كبير في خلايا معينة من خلايا الدم البيضاء (ندرة المحببات) □ تصلب العضلات □<br />تم الإبلاغ أيضا عن حالات نادرة جداً من الأعراض الجانبية التالية بعد العلاج باستخدام مضادات الكينولون الحيوية والتي من المحتمل أن تحدث أيضاً عند استخدام أڤورس:<br />نوع خاص من انخفاض عدد خلايا الدم الحمراء (فقر الدم الانحلالي) □ ارتفاع مستويات الكالسيوم في الدم □ تصلب العضلات ارتفاع مستويات الصوديوم في الدم □<br />زيادة حساسية الجلد لأشعة الشمس أو الأشعة فوق البنفسجية. □ تفاعلات عضلية تشمل تلف الخلايا العضلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول الأطفال.</p><p>لا يحفظ بدرجة حرارة أعلى من ۳۰ &deg;م. □<br />لا ينبغي استعمال أڤورس بعد تاريخ انتهاء الصلاحية الموجود على العلبة وعلى شريط الدواء. □<br />لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أو المنزلي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه الاجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي موكسيفلوكساسين. كل قرص مغلف يحتوي على ٤۰۰ ملغم موكسيفلوكساسين على هيئة موكسيفلوكساسين هيدروكلورايد.</p><p>المكونات الأخرى هي: سيلولوز بلوري مكروي، رذاذ مانيتول المجفف، غليكولات نشا الصوديوم نوع أ، سيليكا غروية لامائية، ستيارات المغنيزيوم، أوبادراي وردي □<br />الأبيض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو الشكل الصيدلاني لأڤورس ووصفه وحجم عبوته:<br />من جانب واحد و جلية من الجانب الآخر. &ldquo;MX أقراص أڤورس ٤۰۰ ملغم هي أقراص مغلفة مستطيلة الشكل مسطحة، ثنائية التحدب ولونها أحمر قاتم، منقوش عليها &rdquo; 4 □<br />علب تحتوي على ٥ أقراص من أقراص أڤورس ٤۰۰ المحفوظة في أشرطة. □<br />علب تحتوي على ۷ أقراص من أقراص أڤورس ٤۰۰ المحفوظة في أشرطة. □<br />،۲۳٤۰ - ۲۳۳٤ - ۲۳٥٤ - ۲۳٥۳ - ۲۳٥٦ - المملكة العربية السعودية: للإبلاغ عن الأعراض الجانبية: المركزالوطني للتيقظ والسلامة الدوائية: هاتف: ۰۰۹٦٦۱۱۲۰۳۸۲۲۲ ، تحويلة: ۲۳۱۷<br />npc.drug@sfda.gov.sa : فاكس: ۰۰۹٦٦۱۱۲۰٥۷٦٦۲ ، الهاتف المجاني: ۸۰۰۲٤۹۰۰۰۰ ، البريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الاردنية لانتاج الادوية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نيسان ۲۰۱۸
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AVORES 400 film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Microcrystalline Cellulose 100 Micrometer 113.37 
Mannitol Spray Dried 69.19 
Sodium Starch Glycolate type A 19.88 
Colloidal Anhydrous Silica 15.41 
Magnesium Stearate 09.59 
Opadry II 33G24737 Pink 25.00
 Purified Water - 
White Beeswax -
*For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dull Red Shallow biconvex oblong film coated tablets, debossed with “MX4” on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>AVORES 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to Moxifloxacin (see sections 4.4, 4.8 and 5.1). Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed:<br /> Acute bacterial sinusitis (adequately diagnosed)<br /> Acute exacerbations of chronic bronchitis (adequately diagnosed)<br /> Community acquired pneumonia, except severe cases<br /> Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess.<br />AVORES 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing Moxifloxacin resistance of Neisseria gonorrhoeae unless Moxifloxacin-resistant Neisseria gonorrhoeae can be excluded (see sections 4.4 and 5.1).<br />AVORES 400 mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous Moxifloxacin for the following indications:<br /> Community-acquired pneumonia<br /> Complicated skin and skin structure infections<br />AVORES 400 mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community-acquired pneumonia.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>recommended dose is one 400 mg film-coated tablet once daily.<br />Renal/hepatic impairment<br />No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).<br />There is insufficient data in patients with impaired liver function (see section 4.3).<br />Other special populations<br />No adjustment of dosage is required in the elderly and in patients with low bodyweight.<br />Paediatric population<br />Moxifloxacin is contraindicated in children and adolescents (&lt; 18 years). Efficacy and safety of Moxifloxacin in children and adolescents have not been established (see section 4.3).</p><p>Method of administration<br />The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.</p><p>Duration of administration<br />AVORES 400 mg film-coated tablets should be used for the following treatment durations:<br /> Acute exacerbation of chronic bronchitis 5 - 10 days<br /> Community acquired pneumonia 10 days<br /> Acute bacterial sinusitis 7 days<br /> Mild to moderate pelvic inflammatory disease 14 days<br />AVORES 400 mg film-coated tablets have been studied in clinical trials for up to 14 days treatment.<br />Sequential (intravenous followed by oral) therapy<br />In clinical studies with sequential therapy most patients switched from intravenous to oral therapy within 4 days (community-acquired pneumonia) or 6 days (complicated skin and skin structure infections). The recommended total duration of intravenous and oral treatment is 7 -14 days for community-acquired pneumonia and 7 -21 days for complicated skin and skin structure infections</p><p>The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to Moxifloxacin, other quinolones or to any of the excipients listed in section 6.1.
 Pregnancy and lactation (see section 4.6).
 Patients below 18 years of age.
 Patients with a history of tendon disease/disorder related to quinolone treatment.
 Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to Moxifloxacin, in the form of QT prolongation. For reasons of drug safety, Moxifloxacin is therefore contraindicated in patients with:
 Congenital or documented acquired QT prolongation
 Electrolyte disturbances, particularly in uncorrected hypokalaemia
 Clinically relevant bradycardia
 Clinically relevant heart failure with reduced left-ventricular ejection fraction
 Previous history of symptomatic arrhythmias
 Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5).
 Due to limited clinical data, Moxifloxacin is also contraindicated in patients with impaired liver function (Child Pugh C) and in patients with transaminases increase > 5fold ULN.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The benefit of Moxifloxacin treatment especially in infections with a low degree of severity should be balanced with the information contained in the warnings and precautions section.<br />Prolongation of QTc interval and potentially QTc-prolongation-related clinical conditions<br />Moxifloxacin has been shown to prolong the QTc interval on the electrocardiogram in some patients. In the analysis of ECGs obtained in the clinical trial program, QTc prolongation with Moxifloxacin was 6 msec &plusmn; 26 msec, 1.4% compared to baseline. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.<br />Medication that can reduce potassium levels should be used with caution in patients receiving Moxifloxacin (see also sections 4.3 and 4.5).<br />Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients), such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. torsade de pointes) and cardiac arrest (see also section 4.3). The magnitude of QT prolongation&nbsp;</p><p>may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded.<br />If signs of cardiac arrhythmia occur during treatment with Moxifloxacin, treatment should be stopped and an ECG should be performed.<br />Hypersensitivity/allergic reactions<br />Hypersensitivity and allergic reactions have been reported for fluoroquinolones including Moxifloxacin after first administration. Anaphylactic reactions can progress to a life-threatening shock, even after the first administration. In these cases Moxifloxacin should be discontinued and suitable treatment (e.g. treatment for shock) initiated.<br />Severe liver disorders<br />Cases of fulminant hepatitis potentially leading to liver failure (including fatal cases) have been reported with Moxifloxacin (see section 4.8). Patients should be advised to contact their doctor prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy.<br />Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur.<br />Serious bullous skin reactions<br />Cases of bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with Moxifloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.<br />Patients predisposed to seizures<br />Quinolones are known to trigger seizures. Use should be with caution in patients with CNS disorders or in the presence of other risk factors which may predispose to seizures or lower the seizure threshold. In case of seizures, treatment with Moxifloxacin should be discontinued and appropriate measures instituted.<br />Peripheral neuropathy<br />Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesias, hypoaesthesias, dysaesthesias, or weakness have been reported in patients receiving quinolones including Moxifloxacin. Patients under treatment with Moxifloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop (see section 4.8).<br />Psychiatric reactions<br />Psychiatric reactions may occur even after the first administration of quinolones, including Moxifloxacin. In very rare cases depression or psychotic reactions have progressed to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4.8). In the&nbsp;event that the patient develops these reactions, Moxifloxacin should be discontinued and appropriate measures instituted. Caution is recommended if Moxifloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.<br />Antibiotic-associated diarrhoea incl. colitis<br />Antibiotic-associated diarrhoea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and Clostridium difficile-associated diarrhoea, has been reported in association with the use of broad spectrum antibiotics including Moxifloxacin and may range in severity from mild diarrhoea to fatal colitis. Therefore it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of Moxifloxacin. If AAD or AAC is suspected or confirmed, ongoing treatment with antibacterial agents, including Moxifloxacin, should be discontinued and adequate therapeutic measures should be initiated immediately. Furthermore, appropriate infection control measures should be undertaken to reduce the risk of transmission. Drugs inhibiting peristalsis are contraindicated in patients who develop serious diarrhoea.<br />Patients with myasthenia gravis<br />Moxifloxacin should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated.<br />Tendon inflammation, tendon rupture<br />Tendon inflammation and rupture (especially Achilles tendon), sometimes bilateral, may occur with quinolone therapy including Moxifloxacin, even within 48 hours of starting treatment and have been reported up to several months after discontinuation of therapy. The risk of tendinitis and tendon rupture is increased in elderly patients and in those treated concurrently with corticosteroids. At the first sign of pain or inflammation, patients should discontinue treatment with Moxifloxacin, rest the affected limb(s) and consult their doctor immediately in order to initiate appropriate treatment (e.g. immobilisation) for the affected tendon. (see sections 4.3 and 4.8).<br />Patients with renal impairment<br />Elderly patients with renal disorders should use Moxifloxacin with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure.<br />Vision disorders<br />If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).<br />Dysglycemia<br />As with all fluoroquinolones, disturbances in blood glucose, including both hypoglycemia and hyperglycemia have been reported with Moxifloxacin. In Moxifloxacin-treated patients, dysglycemia occurred predominantly in elderly diabetic patients receiving concomitant&nbsp;</p><p>treatment with an oral hypoglycemic agent (e.g. sulfonylurea) or with insulin. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).<br />Prevention of photosensitivity reactions<br />Quinolones have been shown to cause photosensitivity reactions in patients. However, studies have shown that Moxifloxacin has a lower risk to induce photosensitivity. Nevertheless patients should be advised to avoid exposure to either UV irradiation or extensive and/or strong sunlight during treatment with Moxifloxacin.<br />Patients with glucose-6-phosphate dehydrogenase deficiency<br />Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. Therefore, Moxifloxacin should be used with caution in these patients.<br />Patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.<br />Patients with pelvic inflammatory disease<br />For patients with complicated pelvic inflammatory disease (e.g. associated with a tubo-ovarian or pelvic abscess), for whom an intravenous treatment is considered necessary, treatment with AVORES 400 mg film-coated tablets is not recommended.<br />Pelvic inflammatory disease may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae. Therefore in such cases empirical Moxifloxacin should be co-administered with another appropriate antibiotic (e.g. a cephalosporin) unless Moxifloxacin-resistant Neisseria gonorrhoeae can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.<br />Patients with special cSSSi<br />Clinical efficacy of intravenous Moxifloxacin in the treatment of severe burn infections, fasciitis and diabetic foot infections with osteomyelitis has not been established.<br />Interference with biological tests<br />Moxifloxacin therapy may interfere with the Mycobacterium spp. culture test by suppression of mycobacterial growth causing false negative results in samples taken from patients currently receiving Moxifloxacin.<br />Patients with MRSA infections<br />Moxifloxacin is not recommended for the treatment of MRSA infections. In case of a suspected or confirmed infection due to MRSA, treatment with an appropriate antibacterial agent should be started (see section 5.1).</p><p>Paediatric population<br />Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of Moxifloxacin in children and adolescents &lt; 18 years is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions with medicinal products<br />An additive effect on QT interval prolongation of Moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. Therefore, co-administration of Moxifloxacin with any of the following medicinal products is contraindicated (see also section 4.3):<br /> Anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)<br /> Anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)<br /> Antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)<br /> Tricyclic antidepressive agents<br /> Certain antimicrobial agents (saquinavir, sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine)<br /> Certain antihistaminics (terfenadine, astemizole, mizolastine)<br /> Others (cisapride, vincamine IV, bepridil, diphemanil).<br />Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels (e.g. loop and thiazide-type diuretics, laxatives and enemas [high doses], corticosteroids, amphotericin B) or medication that is associated with clinically significant bradycardia.<br />An interval of about 6 hours should be left between administration of agents containing bivalent or trivalent cations (e.g. antacids containing magnesium or aluminium, didanosine tablets, sucralfate and agents containing iron or zinc) and administration of Moxifloxacin.<br />Concomitant administration of charcoal with an oral dose of 400 mg Moxifloxacin led to a pronounced prevention of drug absorption and a reduced systemic availability of the drug by more than 80%. Therefore, the concomitant use of these two drugs is not recommended (except for overdose cases, see also section 4.9).<br />After repeated dosing in healthy volunteers, Moxifloxacin increased Cmax of digoxin by approximately 30% without affecting AUC or trough levels. No precaution is required for use with digoxin.<br />In studies conducted in diabetic volunteers, concomitant administration of oral Moxifloxacin with glibenclamide resulted in a decrease of approximately 21% in the peak plasma concentrations of glibenclamide. The combination of glibenclamide and Moxifloxacin could theoretically</p><p>result in a mild and transient hyperglycaemia. However, the observed pharmacokinetic changes for glibenclamide did not result in changes of the pharmacodynamic parameters (blood glucose, insulin). Therefore no clinically relevant interaction was observed between Moxifloxacin and glibenclamide.<br />Changes in INR<br />A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins. The infectious and inflammatory conditions, age and general status of the patient appear to be risk factors. Under these circumstances, it is difficult to evaluate whether the infection or the treatment caused the INR (international normalised ratio) disorder. A precautionary measure would be to more frequently monitor the INR. If necessary, the oral anticoagulant dosage should be adjusted as appropriate.<br />Clinical studies have shown no interactions following concomitant administration of Moxifloxacin with: ranitidine, probenecid, oral contraceptives, calcium supplements, morphine administered parenterally, theophylline, cyclosporine or itraconazole.<br />In vitro studies with human cytochrome P450 enzymes supported these findings. Considering these results a metabolic interaction via cytochrome P450 enzymes is unlikely.<br />Interaction with food<br />Moxifloxacin has no clinically relevant interaction with food including dairy products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of Moxifloxacin in human pregnancy has not been evaluated. Animal studies have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, Moxifloxacin must not be used in pregnant women (see section 4.3).<br />Breastfeeding<br />There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of Moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during Moxifloxacin therapy (see section 4.3).</p><p>Fertility<br />Animal studies do not indicate impairment of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Moxifloxacin on the ability to drive and use machines have been performed. However, fluoroquinolones including Moxifloxacin may result in an impairment of the patient&#39;s ability to drive or operate machinery due to CNS reactions (e.g. dizziness; acute, transient loss of vision, see section 4.8) or acute and short lasting loss of consciousness (syncope, see section 4.8). Patients should be advised to see how they react to Moxifloxacin before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions based on all clinical trials with Moxifloxacin 400 mg (oral and sequential therapy) sorted by frequencies are listed below:<br />Apart from nausea and diarrhoea all adverse reactions were observed at frequencies below 3%.<br />Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as:<br /> Common (&ge; 1/100 to &lt; 1/10)<br /> Uncommon (&ge; 1/1,000 to &lt; 1/100)<br /> Rare (&ge; 1/10,000 to &lt; 1/1,000)<br /> Very rare (&lt; 1/10,000)</p><p>There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with Moxifloxacin: hypernatraemia, hypercalcaemia, haemolytic anaemia, rhabdomyolysis, photosensitivity reactions (see section 4.4).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Superinfections due to resistant bacteria or fungi e.g. oral</p><p>and vaginal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia Leucopenia(s) Neutropenia Thrombocytopenia Thrombocythemia Blood eosinophilia Prothrombin time prolonged/INR increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prothrombin level increased/INR decreased</p><p>Agranulocytosis</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic&nbsp;&nbsp;&nbsp;&nbsp; reaction (see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylaxis incl. very rarely life-threatening shock (see section 4.4)</p><p>Allergic oedema/ angiooedema (incl.&nbsp;&nbsp;&nbsp;&nbsp; laryngeal oedema, potentially&nbsp;&nbsp;&nbsp; life- threatening,&nbsp;&nbsp;&nbsp; see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidemia</p></td><td style="vertical-align:top"><p>Hyperglycemia Hyperuricemia</p></td><td style="vertical-align:top"><p>Hypoglycemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety reactions</p><p>Psychomotor hyperactivity/ agitation</p></td><td style="vertical-align:top"><p>Emotional lability</p><p>Depression&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (in very rare cases potentially culminating in self-injurious behaviour, such as&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p><p>Hallucination</p></td><td style="vertical-align:top"><p>Depersonalization</p><p>Psychotic reactions (potentially culminating in self-injurious behaviour, such as suicidal ideations/ thoughts,or suicide attempts, see section 4.4)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache Dizziness</p></td><td style="vertical-align:top"><p>Par- and Dysaesthesia</p><p>Taste disorders (incl.&nbsp;&nbsp;&nbsp; ageusia&nbsp;&nbsp;&nbsp; in very rare cases)</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>Smell&nbsp;&nbsp;&nbsp; disorders (incl. anosmia)</p><p>Abnormal dreams</p></td><td style="vertical-align:top"><p>Hyperaesthesia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Confusion and disorientation</p><p>Sleep disorders (predominantly insomnia)</p><p>Tremor</p></td><td style="vertical-align:top"><p>Disturbed coordination (incl. gait disturbances, esp. due to dizziness or vertigo)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo Somnolence</p></td><td style="vertical-align:top"><p>Seizures incl. grand mal convulsions (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Disturbed attention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Speech disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amnesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Peripheral neuropathy and polyneuropathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td rowspan="8" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual</p></td><td rowspan="8" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient loss of</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>disturbances&nbsp;&nbsp;&nbsp; incl.</p></td><td style="vertical-align:top"><p>vision (especially</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>diplopia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p></td><td style="vertical-align:top"><p>in the course of</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blurred&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision</p></td><td style="vertical-align:top"><p>CNS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(especially in the</p></td><td style="vertical-align:top"><p>see sections 4.4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>course&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp; CNS</p></td><td style="vertical-align:top"><p>and 4.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>reactions,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; see</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</strong></p><p><strong>labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing impairment incl. deafness (usually reversible)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>QT</p><p>prolongation in patients with hypokalaemia</p></td><td style="vertical-align:top"><p>QT&nbsp;&nbsp;&nbsp;&nbsp; prolongation (see section 4.4)</p><p>Palpitations</p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmias</p><p>Syncope&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i.e., acute&nbsp;&nbsp; and &nbsp;short</p></td><td style="vertical-align:top"><p>Unspecified arrhythmias</p><p>Torsade&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; de</p><p>Pointes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (see</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(see&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sections</p><p>4.3 and 4.4)</p></td><td style="vertical-align:top"><p>Tachycardia Atrial fibrillation</p><p>Angina pectoris</p></td><td style="vertical-align:top"><p>lasting&nbsp;&nbsp;&nbsp; loss&nbsp;&nbsp;&nbsp; of consciousness)</p></td><td style="vertical-align:top"><p>section 4.4)</p><p>Cardiac&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arrest (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Hypertension</p><p>Hypotension</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea (including asthmatic conditions)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Vomiting</p><p>Gastrointestinal and abdominal pains</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Decreased appetite and food intake</p><p>Constipation Dyspepsia Flatulence Gastritis Increased amylase</p></td><td style="vertical-align:top"><p>Dysphagia</p><p>Stomatitis</p><p>Antibiotic associated colitis (incl.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pseudo- membranous colitis,&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp; very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cases associated&nbsp;&nbsp;&nbsp; with life-threatening complications, see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Increase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in transaminases</p></td><td style="vertical-align:top"><p>Hepatic impairment&nbsp;&nbsp;&nbsp; (incl. LDH increase)</p><p>Increased bilirubin</p><p>Increased gamma- glutamyl- transferase</p><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis (predominantly cholestatic)</p></td><td style="vertical-align:top"><p>Fulminant hepatitis potentially leading&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp; life- threatening&nbsp;&nbsp;&nbsp; liver failure (incl. fatal cases, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus Rash Urticaria Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bullous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin</p><p>reactions&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; like Stevens-Johnson syndrome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or toxic&nbsp;&nbsp;&nbsp;&nbsp; epidermal necrolysis (potentially&nbsp;&nbsp;&nbsp; life- threatening,&nbsp;&nbsp;&nbsp;&nbsp; see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendonitis&nbsp;&nbsp;&nbsp;&nbsp; (see section 4.4)</p></td><td style="vertical-align:top"><p>Tendon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rupture (see section 4.4)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle cramp</p><p>Muscle twitching</p><p>Muscle weakness</p></td><td style="vertical-align:top"><p>Arthritis Muscle rigidity</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Renal impairment (incl. increase in BUN and creatinine)</p><p>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders&nbsp;&nbsp;&nbsp;&nbsp; and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Feeling&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unwell (predominantly asthenia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or fatigue)</p><p>Painful conditions (incl. pain in back, chest, pelvic and extremities)</p><p>Sweating</p></td><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with Moxifloxacin: hypernatraemia, hypercalcaemia, haemolytic anaemia, rhabdomyolysis, photosensitivity reactions (see section 4.4).</p><p>To report any side effect (s):</p><p>Saudi Arabia: National Pharmacovigilance &amp; Drug Safety Centre (NPC)</p><p>q&nbsp; Fax: +966-11-205-7662</p><p>q&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354- 2334-2340.</p><p>q&nbsp; Toll free phone: 8002490000</p><p>q&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>q&nbsp; Website: www.sfda.gov.sa/npc</p><p>No specific countermeasures after accidental overdose are recommended. In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Concomitant administration of charcoal with a dose of 400 mg oral Moxifloxacin will reduce systemic availability of the drug by more than 80%. The use of charcoal early during absorption</p><p>may be useful to prevent excessive increase in the systemic exposure to Moxifloxacin in cases of oral overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Quinolone antibacterials, fluoroquinolones<br />ATC Code: J01MA14<br />Mechanism of action<br />Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens.<br />The bactericidal action of Moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the norA or pmrA genes seen in certain Gram-positive bacteria.<br />Pharmacodynamic investigations have demonstrated that Moxifloxacin exhibits a concentration dependent killing rate. Minimum bactericidal concentrations (MBC) were found to be in the range of the minimum inhibitory concentrations (MIC).<br />Effect on the intestinal flora in humans<br />The following changes in the intestinal flora were seen in volunteers following oral administration of Moxifloxacin: Escherichia coli, Bacillus spp., Enterococcus spp., and Klebsiella spp. were reduced, as were the anaerobes Bacteroides vulgatus, Bifidobacterium spp., Eubacterium spp., and Peptostreptococcus spp.. For Bacteroides fragilis there was an increase. These changes returned to normal within two weeks.<br />Mechanism of resistance<br />Resistance mechanisms that inactivate penicillins, cephalosporins, aminoglycosides, macrolides and tetracyclines do not interfere with the antibacterial activity of Moxifloxacin. Other resistance mechanisms such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may also effect susceptibility to Moxifloxacin.<br />In vitro resistance to Moxifloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Moxifloxacin is a poor substrate for active efflux mechanisms in Gram-positive organisms.<br />Cross-resistance is observed with other fluoroquinolones. However, as Moxifloxacin inhibits both topoisomerase II and IV with similar activity</p><p>in some Gram-positive bacteria, such bacteria may be resistant to other quinolones, but susceptible to Moxifloxacin.<br />Breakpoints<br />EUCAST clinical MIC and disk diffusion breakpoints for Moxifloxacin (01.01.2011):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus spp.</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 24 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 21 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>S. pneumoniae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 22 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&ge; 22 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>Groups A, B, C, G</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 18 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 15 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>M. catarrhalis</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 23 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&lt; 23 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 20 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p><p>&lt; 17 mm</p></td></tr><tr><td style="vertical-align:top"><p>Non-species&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; related breakpoints*</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Non-species related breakpoints have been determined mainly on the basis of pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and are not for use with species where interpretative criteria remain to be determined.</p><p><u>Microbiological Susceptibility</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought where the local prevalence of resistance is such that utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Gardnerella vaginalis</em></p><p><em>Staphylococcus aureus</em>* (methicillin-susceptible)</p><p><em>Streptococcus agalactiae </em>(Group B)</p><p>Streptococcus milleri group* (<em>S. anginosus, S. constellatus and S. intermedius</em>)</p><p><em>Streptococcus pneumoniae</em>* <em>Streptococcus pyogenes</em>* (Group A)</p><p><em>Streptococcus viridans </em>group (<em>S. viridans, S. mutans, S. mitis, S. sanguinis,</em></p><p><em>S. salivarius, S. thermophilus</em>)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter baumanii Haemophilus influenzae* Haemophilus parainfluenzae</em>* <em>Legionella pneumophila</em></p><p><em>Moraxella (Branhamella) catarrhalis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Fusobacterium spp. Prevotella spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><u>&nbsp;</u><u>&ldquo;Other&rdquo; micro-organisms</u></p><p><em>Chlamydophila (Chlamydia) pneumoniae* Chlamydia trachomatis*</em></p><p><em>Coxiella burnetii Mycoplasma genitalium Mycoplasma hominis</em></p><p><em>Mycoplasma pneumoniae*</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis* Enterococcus faecium*</em></p><p><em>Staphylococcus aureus (methicillin-resistant)<sup>+</sup></em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Enterobacter cloacae* Escherichia coli* Klebsiella pneumoniae*# Klebsiella oxytoca Neisseria gonorrhoeae*+ Proteus mirabilis*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Bacteroides fragilis* Peptostreptococcus spp.*</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p>*Activity has been satisfactorily demonstrated in susceptible strains in clinical studies in the approved clinical indications.</p><p>#ESBL-producing strains are commonly resistant to fluoroquinolones</p><p>+Resistance rate &gt; 50% in one or more countries</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption and Bioavailability<br />Following oral administration Moxifloxacin is rapidly and almost completely absorbed. The absolute bioavailability amounts to approximately 91%.<br />Pharmacokinetics are linear in the range of 50 - 800 mg single dose and up to 600 mg once daily dosing over 10 days. Following a 400 mg oral dose peak concentrations of 3.1 mg/l are reached within 0.5 - 4 h post administration. Peak and trough plasma concentrations at steady-state (400 mg once daily) were 3.2 and 0.6 mg/l, respectively. At steady-state the exposure within the dosing interval is approximately 30% higher than after the first dose.<br />Distribution<br />Moxifloxacin is distributed to extravascular spaces rapidly; after a dose of 400 mg an AUC of 35 m∙gh/l is observed. The steady-state volume of distribution (Vss) is approximately 2 l/kg. In vitro and ex vivo experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug. Moxifloxacin is mainly bound to serum albumin.</p><p>The following peak concentrations (geometric mean) were observed following administration of a single oral dose of 400 mg Moxifloxacin:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Tissue</strong></p></td><td style="vertical-align:top"><p><strong>Concentration</strong></p></td><td style="vertical-align:top"><p><strong>Site: Plasma ratio</strong></p></td></tr><tr><td style="vertical-align:top"><p>Plasma</p></td><td style="vertical-align:top"><p>3.1 mg/l</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Saliva</p></td><td style="vertical-align:top"><p>3.6 mg/l</p></td><td style="vertical-align:top"><p>0.75 - 1.3</p></td></tr><tr><td style="vertical-align:top"><p>Blister fluid</p></td><td style="vertical-align:top"><p>1.61 mg/l</p></td><td style="vertical-align:top"><p>1.7<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Bronchial mucosa</p></td><td style="vertical-align:top"><p>5.4 mg/kg</p></td><td style="vertical-align:top"><p>1.7 - 2.1</p></td></tr><tr><td style="vertical-align:top"><p>Alveolar macrophages</p></td><td style="vertical-align:top"><p>56.7 mg/kg</p></td><td style="vertical-align:top"><p>18.6 - 70.0</p></td></tr><tr><td style="vertical-align:top"><p>Epithelial lining fluid</p></td><td style="vertical-align:top"><p>20.7 mg/l</p></td><td style="vertical-align:top"><p>5 - 7</p></td></tr><tr><td style="vertical-align:top"><p>Maxillary sinus</p></td><td style="vertical-align:top"><p>7.5 mg/kg</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Ethmoid sinus</p></td><td style="vertical-align:top"><p>8.2 mg/kg</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Nasal polyps</p></td><td style="vertical-align:top"><p>9.1 mg/kg</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial fluid</p></td><td style="vertical-align:top"><p>1.02 mg/l</p></td><td style="vertical-align:top"><p>0.8 - 1.4<sup>2,3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Female genital tract*</p></td><td style="vertical-align:top"><p>10.24 mg/kg</p></td><td style="vertical-align:top"><p>1.72<sup>4</sup></p></td></tr></tbody></table><p>* intravenous administration of a single 400 mg dose</p><p>1 10 h after administration</p><p>2 unbound concentration</p><p>3 from 3 h up to 36 h post dose 4 at the end of infusion <u>Biotransformation</u></p><p>Moxifloxacin undergoes Phase II biotransformation and is excreted via renal and biliary/faecal pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2). M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.</p><p>In clinical Phase I and in vitro studies no metabolic pharmacokinetic interactions with other drugs undergoing Phase I biotransformation involving cytochrome P450 enzymes were observed. There is no indication of oxidative metabolism.</p><p><u>Elimination</u></p><p>Moxifloxacin is eliminated from plasma with a mean terminal half life of approximately 12 hours. The mean apparent total body clearance following a 400 mg dose ranges from 179 to 246 ml/min. Renal clearance amounted to about 24 - 53 ml/min suggesting partial tubular reabsorption of the drug from the kidneys.</p><p>After a 400 mg dose, recovery from urine (approximately 19% for unchanged drug, approximately 2.5% for M1, and approximately 14% for M2) and faeces (approximately 25% of unchanged drug, approximately 36% for M1, and no recovery for M2) totalled to approximately 96%.</p><p>Concomitant administration of Moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.</p><p><em>Elderly and patients with low body weight</em></p><p>Higher plasma concentrations are observed in healthy volunteers with low body weight (such as women) and in elderly volunteers.</p><p><em>Renal impairment</em></p><p>The pharmacokinetic properties of Moxifloxacin are not significantly different in patients with renal impairment (including creatinine clearance &gt; 20 ml/min/1.73 m<sup>2</sup>). As renal function decreases, concentrations of the M2 metabolite (glucuronide) increase by up to a factor of 2.5 (with a creatinine clearance of &lt; 30 ml/min/1.73 m<sup>2</sup>).</p><p><em>Hepatic impairment</em></p><p>On the basis of the pharmacokinetic studies carried out so far in patients with liver failure (Child Pugh A, B), it is not possible to determine whether there are any differences compared with healthy volunteers. Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers. There is insufficient experience in the clinical use of Moxifloxacin in patients with impaired liver function.</p><table border="1" cellspacing="0" cellpadding="0"><tbody></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on the haematopoetic system (slight decreases in the number of erythrocytes and platelets) were seen in rats and monkeys. As with other quinolones, hepatotoxicity (elevated liver enzymes and vacuolar degeneration) was seen in rats, monkeys and dogs. In monkeys CNS toxicity (convulsions) occurred. These effects were seen only after treatment with high doses of Moxifloxacin or after prolonged treatment.<br />Moxifloxacin, like other quinolones, was genotoxic in in vitro tests using bacteria or mammalian cells. Since these effects can be explained by an interaction with the gyrase in bacteria and - at higher concentrations - by an interaction with the topoisomerase II in mammalian cells, a threshold concentration for genotoxicity can be assumed. In in vivo tests, no evidence of genotoxicity was found despite the fact that very high Moxifloxacin doses were used. Thus, a sufficient margin of safety to the therapeutic dose in man can be provided. Moxifloxacin was non-carcinogenic in an initiation-promotion study in rats.<br />Many quinolones are photoreactive and can induce phototoxic, photomutagenic and photocarcinogenic effects. In contrast, Moxifloxacin was proven to be devoid of phototoxic and photogenotoxic properties when tested in a comprehensive programme of in vitro and in vivo studies. Under the same conditions other quinolones induced effects.</p><p>At high concentrations, Moxifloxacin is an inhibitor of the rapid component of the delayed rectifier potassium current of the heart and may thus cause prolongations of the QT interval. Toxicological studies performed in dogs using oral doses of &ge; 90 mg/kg leading to plasma concentrations &ge; 16 mg/l caused QT prolongations, but no arrhythmias. Only after very high cumulative intravenous administration of more than 50fold the human dose (&gt; 300 mg/kg), leading to plasma concentrations of &ge; 200 mg/l (more than 40fold the therapeutic level), reversible, non-fatal ventricular arrhythmias were seen.<br />Quinolones are known to cause lesions in the cartilage of the major diarthrodial joints in immature animals. The lowest oral dose of Moxifloxacin causing joint toxicity in juvenile dogs was four times the maximum recommended therapeutic dose of 400 mg (assuming a 50 kg bodyweight) on a mg/kg basis, with plasma concentrations two to three times higher than those at the maximum therapeutic dose.<br />Toxicity tests in rats and monkeys (repeated dosing up to six months) revealed no indication regarding an oculotoxic risk. In dogs, high oral doses (&ge; 60 mg/kg) leading to plasma concentrations &ge; 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.<br />Reproductive studies performed in rats, rabbits and monkeys indicate that placental transfer of Moxifloxacin occurs. Studies in rats (p.o. and i.v.) and monkeys (p.o.) did not show evidence of teratogenicity or impairment of fertility following administration of Moxifloxacin. A slightly increased incidence of vertebral and rib malformations was observed in foetuses of rabbits but only at a dose (20 mg/kg i.v.) which was associated with severe maternal toxicity. There was an increase in the incidence of abortions in monkeys and rabbits at human therapeutic plasma concentrations. In rats, decreased foetal weights, an increased prenatal loss, a slightly increased duration of pregnancy and an increased spontaneous activity of some male and female offspring was observed at doses which were 63 times the maximum recommended dose on a mg/kg basis with plasma concentrations in the range of the human therapeutic dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose 100 Micrometer<br /> Mannitol Spray Dried<br /> Sodium Starch Glycolate type A<br /> Colloidal Anhydrous Silica<br /> Magnesium Stearate<br /> Opadry II 33G24737 Pink<br /> Purified Water<br /> White Beeswax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Boxes of 5 blistered tablets of AVORES 400.<br /> Boxes of 7 blistered tablets of AVORES 400.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2018.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>